Pulse Biosciences (NASDAQ:PLSE) Insider Sells $504,000.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at $1,091,109.60. This trade represents a 31.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total transaction of $429,000.00.

Pulse Biosciences Price Performance

Shares of PLSE stock traded up $1.33 during trading hours on Wednesday, reaching $25.25. The company had a trading volume of 466,845 shares, compared to its average volume of 386,842. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $26.30. The company has a 50 day moving average of $14.97 and a 200 day moving average of $15.66. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently made changes to their positions in PLSE. Bank of America Corp DE boosted its stake in Pulse Biosciences by 2.7% in the 3rd quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock valued at $14,248,000 after purchasing an additional 21,424 shares during the period. Geode Capital Management LLC increased its holdings in Pulse Biosciences by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock valued at $7,538,000 after buying an additional 33,744 shares during the period. Portolan Capital Management LLC acquired a new position in shares of Pulse Biosciences in the 3rd quarter valued at approximately $1,809,000. UBS Group AG lifted its stake in Pulse Biosciences by 53.4% during the third quarter. UBS Group AG now owns 76,856 shares of the company’s stock worth $1,360,000 after purchasing an additional 26,739 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its stake in Pulse Biosciences by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after buying an additional 1,886 shares in the last quarter. Institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PLSE. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $26.00.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.